A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

← catalyst calendar

NCT05362773 · readout ≤ 102 d

Sponsored by MacroGenics (industry) · MGNX — their whole pipeline →.

Phase

Phase 1

Status

Active, not recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

130estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-07-13

actual

When the study began enrolling

Primary completion

Nov 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

May 2027

estimated

The whole study's end, after follow-up

First posted

2022-05-05

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-28

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Leukemia, Acute Myeloid
Myelodysplastic Syndromes
Classical Hodgkin Lymphoma
Leukemia, B-cell
Leukemia, Hairy Cell
Mastocytosis, Aggressive Systemic
Blastic Plasmacytoid Dendritic Cell Neoplasm
Chronic Myeloid Leukemia

Intervention

Drug: MGD024

Primary outcomes

what the primary-completion date above is the date OF

Number of severe side effects in patients receiving MGD024

measured First 28 days of the study

Number and types of adverse events (AEs), including serious adverse events (SAEs), and AEs leading to treatment discontinuation.

measured Throughout study participation, up to 12 months.

Permalink · MGNX's whole pipeline · Catalyst calendar · Every registered study · What changed